Clinical Trials in Tennessee

Showing 7721-7740 of 20,239 trials

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

NCT04296864

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).

Atopic Keratoconjunctivitis

Andover Eye Associates42 participantsStarted Feb 2020

Los Angeles, California, United States • Littleton, Colorado, United States • Hollywood, Florida, United States +17 more locations

TERMINATEDPhase 1/229 miles

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

NCT02152956

Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the Maximum Tolerated Dose and Schedule (MTDS) Expansion Cohort Segment (closed). Having characterized safety and determined the maximum tolerated dose and schedule, the primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR or CRh. Starting with Cycle 2, patients who are benefiting from flotetuzumab may receive up to a maximum of 8 cycles of treatment. Patients will receive daily increasing doses of flotetuzumab for the first week of Cycle 1 (Lead-In Dosing) followed by 3 weeks of continuous intravenous infusion at a the assigned dose. Subsequent cycles are each 4 weeks of continuous infusion at the assigned dose. Dosing may continue for up to 8 cycles. Follow up visits may continue for 6 months after treatment is discontinued.

AML

MacroGenics244 participantsStarted Jun 2014

Duarte, California, United States • La Jolla, California, United States • San Francisco, California, United States +40 more locations

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Find Trials by Condition in Tennessee

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Pharyngeal Anatomy In Obstructive Sleep Apnea With HRM

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

Robotic Mechanical Coring for the Treatment of Moderate to Severe Facial Wrinkles

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

A Study of Mirikizumab in Participants With Plaque Psoriasis

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip